SOLIGENIX Business Summary

Soligenix, Inc. (SNGX) operates as a late-stage biopharmaceutical firm utilizing a dual-track revenue model centered on Specialized BioTherapeutics and Public Health Solutions. The BioTherapeutics segment targets rare diseases with high unmet needs, primarily through its lead asset HyBryte™ (synthetic hypericin), which is currently undergoing a confirmatory Phase 3 FLASH2 trial for cutaneous T-cell lymphoma (CTCL) with top-line results expected in the second half of 2026. The Public Health Solutions segment generates non-dilutive revenue through multi-year government contracts and grants from BARDA, NIAID, and the DTRA to develop biodefense countermeasures like the RiVax® ricin vaccine and filovirus vaccines using its proprietary ThermoVax® heat stabilization platform. In the competitive arena, Soligenix competes with Emergent BioSolutions in the biodefense space and Kyowa Kirin and Mallinckrodt in the CTCL market, distinguishing itself through its focus on orphan indications and a projected $2 billion global peak sales opportunity across its pipeline. The executive team is led by Dr. Christopher J. Schaber, who has served as Chairman, President, and CEO since 2006, bringing extensive experience from Discovery Laboratories and Centocor. Scientific strategy is directed by SVP and Chief Scientific Officer Dr. Oreola Donini, a specialist in innate defense regulators, while financial operations are managed by CFO Jonathan Guarino, who recently secured a $7.5 million capital infusion to extend the company’s operational runway through 2026. The company’s strategic direction is further guided by a seasoned Board of Directors, including Dr. Jerome Zeldis, former CMO of Celgene, and Gregory Lapointe, former CEO of Sigma-Tau Pharmaceuticals. Backed by institutional investors such as DAFNA Capital Management and supported by the New Jersey NOL tax program, the leadership team is currently focused on achieving pivotal 2026 milestones, including the interim analysis of the FLASH2 study and potential ex-U.S. commercial partnerships.